Close

Vical (VICL) Commences VL-2397 Phase 1

March 7, 2016 6:32 AM EST Send to a Friend
Vical Incorporated (Nasdaq: VICL) announced the initiation of a Phase 1 clinical trial of the company’s novel antifungal, VL-2397. The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login